SCHEMBL6153318

SCHEMBL6153318

Cc1cccc(C2(C(=O)O)CC3CCC(C2)N3C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.49
SLC6A4 P31645 2/20 0.49
SLC6A3 Q01959 2/20 0.49
OPRM1 P35372 6/20 0.47
OPRL1 P41146 5/20 0.47
HDAC4 P56524 1/20 0.45
CCR2 P41597 1/20 0.43
OPRD1 P41143 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GRM5 P41594 4/20 0.40
OPRK1 P41145 2/20 0.39
EGFR P00533 1/20 0.38
PRKACA P17612 1/20 0.38
FRK P42685 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
NEK4 P51957 1/20 0.38
PRKCD Q05655 1/20 0.38
SLK Q9H2G2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11173936 0.85 OPRL1 (0.60) SLC6A2SLC6A4SLC6A3OPRM1OPRL1
SCHEMBL11173935 0.85 OPRL1 (0.60) SLC6A2SLC6A4SLC6A3OPRM1OPRL1
SCHEMBL17222222 0.81 HDAC4 (0.50) SLC6A2SLC6A3OPRM1HDAC4CCR2
SCHEMBL17222220 0.81 HDAC4 (0.50) SLC6A2SLC6A3OPRM1HDAC4CCR2
SCHEMBL1561226 0.77 HDAC4 (0.59) OPRM1OPRL1HDAC4CCR2OPRD1
SCHEMBL7156275 0.75 OPRM1 (0.47) SLC6A2SLC6A4SLC6A3OPRM1OPRL1
SCHEMBL7822328 0.74 HDAC4 (0.69) HDAC4CCR2MEN1KMT2ACYP2C9
SCHEMBL8110741 0.74 HDAC4 (0.65) OPRM1OPRL1HDAC4CCR2OPRD1
Hydrochloric Acid SCHEMBL8106513 0.73 OPRL1 (0.51) SLC6A2SLC6A4SLC6A3OPRM1OPRL1
SCHEMBL7464514 0.71 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3OPRM1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050165057-A1 Novel piperidine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-07-28 US disclosed
EP-1500648-A1 NOVEL PIPERIDINE DERIVATIVE SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed
EP-1337532-A2 COMPOUND FOR CHELATING A METAL, RADIOPHARMACEUTICAL, MANUFACTURING PROCESS THEREFOR, AND DIAGNOSTIC KIT SCHERING AKTIENGESELLSCHAFT (DE) 2003-08-27 EP disclosed
WO-2002044175-A2 COMPOUND FOR CHELATING A METAL, RADIOPHARMACEUTICAL, MANUFACTURING PROCESS THEREFOR, AND DIAGNOSTIC KIT SCHERING AKTIENGESELLSCHAFT (DE) 2002-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165057-A1 Novel piperidine derivative ACAT2, ACAT1, LCAT SLC6A2 3601/4885SLC6A4 2191/4885SLC6A3 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.